Evidence map›Paper›PMID 36068354›Full record

ReviewNature reviews. Rheumatology2022

Global epidemiology of rheumatoid arthritis.

Axel Finckh, Benoît Gilbert, Bridget Hodkinson, Sang-Cheol Bae, Ranjeny Thomas, Kevin D Deane, Deshiré Alpizar-Rodriguez, Kim Lauper

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Rheumatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 514 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
514citing papers in PubMed, 9 pooled it
112.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05979454 unknown statusnot on this mapstarted 2023, after this paper: background citation

Value of Krebs Von Den Lungen-6 Assay in Rheumatoid Artheritis-associated Interstitial Lung Disease

TypeobservationalSponsorAssiut UniversityRan2023 to 2023Enrolled80ConditionsRheumatoid Arthritis-Associated Interstitial Lung DiseaseArmsKrebs von den Lungen-6 (KL6)
NCT06417138 unknown statusnot on this mapstarted 2023, after this paper: background citation

Comparative Effectiveness of Different Drugs Used to Treat Patients in Rheumatoid Arthritis Saudi Database (RASD) The Primary Objective of This Study is to Compare the Effectiveness of Different Biological Disease Modifying Antirheumatic Drugs (bDMARDs) and Targeted Synthetic (tsDMARDs) Using DAS-28-CRP and CDAI Scores.

TypeobservationalSponsorUmm Al-Qura UniversityRan2023 to 2025Enrolled800ConditionsRheumatoid Arthritis RAArmsbiological and targeted synthetic disease modifying anti rheumatic drugs (bDMARDs) and (tsDMARDs)
3 · Its place in the literature

Who cites it

514 citing papers in PubMed, 9 syntheses or guidelines pooled it, 692 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article

454 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 7 countries.

Axel FinckhDivision of Rheumatology, Department of Medicine, Geneva University Hospital (HUG), Geneva, Switzerland. Axel.finckh@hcuge.ch.ORCID 0000-0002-1210-4347
Benoît GilbertDivision of Rheumatology, Department of Medicine, Geneva University Hospital (HUG), Geneva, Switzerland.
Bridget HodkinsonDivision of Rheumatology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.
Sang-Cheol BaeDepartment of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Hanyang University Institute for Rheumatology and Hanyang University Institute of Bioscience and Biotechnology, Seoul, Republic of Korea.ORCID 0000-0003-4658-1093
Ranjeny ThomasThe University of Queensland Diamantina Institute, The University of Queensland, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia.ORCID 0000-0002-0518-8386
Kevin D DeaneUniversity of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0003-2211-4861
Deshiré Alpizar-RodriguezResearch Unit, Colegio Mexicano de Reumatología, Mexico City, Mexico.
Kim LauperDivision of Rheumatology, Department of Medicine, Geneva University Hospital (HUG), Geneva, Switzerland.ORCID 0000-0002-4315-9009
University Hospital of Geneva · CHEl Colegio de México · MXHanyang University Seoul Hospital · KRThe University of Queensland · AUUniversity of Cape Town · ZAUniversity of Colorado Anschutz Medical Campus · USUniversity of Manchester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a systemic autoimmune disease that predominantly affects the joints. The prevalence of RA varies globally, with generally a higher prevalence in industrialized countries, which may be explained by exposures to environmental risk factors, but also by genetic factors, differing demographics and under-reporting in other parts of the world. Over the past three decades, strong trends of the declining severity of RA probably reflect changes in treatment paradigms and overall better management of the disease. Other trends include increasing RA prevalence. Common risk factors for RA include both modifiable lifestyle-associated variables and non-modifiable features, such as genetics and sex. A better understanding of the natural history of RA, and of the factors that contribute to the development of RA in specific populations, might lead to the introduction of specific prevention strategies for this debilitating disease.

Indexed as

Arthritis, RheumatoidHumansPrevalenceRisk Factors

Identifiers

PMID36068354
OpenAlexW4294755189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.